|
OOȍ |
±¹³» Áß°ß Á¦¾à»ç Á¦Á¦¿¬±¸¼Ò °æ·ÂÁ÷ ¸ðÁý
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
06.14 |
|
|
(ÁÖ)ÄɾîÅØ |
±¹³»¿µ¾÷ºÎ ¸ðÁý
°¿ø ¿øÁÖ½Ã, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¿µ¾÷°ü¸®/¿µ¾÷Áö¿ø |
3³â¡è |
ä¿ë½Ã |
06.25 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
Clinical Lead (for Dedicated CRA) ¸ðÁý -ÆĶô¼¿ÄÚ¸®¾Æ
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
4³â¡è |
ä¿ë½Ã |
07.31 |
|
|
¿¥µð±×¸°ÀÇ¿ø |
ÀÓ»óº´¸®»ç ä¿ë
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(2~3³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
02.17 |
|
|
Áö¸à½º(ÁÖ) |
Áö¸à½º¢ß ¸ÞµðÄ®¼Ö·ç¼ÇÁî»ç¾÷ºÎ CRM Excellence Manager ¸ð
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
4³â¡è |
ä¿ë½Ã |
06.28 |
|
|
(ÁÖ)¾¾¾Ø¿¡½ºÄÚ¸®¾Æ |
CRA °æ·Â»ç¿ø ä¿ë/ ¿Ü±¹°è Á¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
ä¿ë½Ã |
02.18 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ - Clinical Lead
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
09.20 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
Clinical Lead (for Dedicated CRA) ¸ðÁý -ÆĶô¼¿ÄÚ¸®¾Æ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
07.25 |
|
|
(ÁÖ)Ƽ¿¤½Ã½ºÅÛ |
Ç°Áú°æ¿µºÎ¹® °æ·ÂÀÚ
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
4³â¡è |
ä¿ë½Ã |
10.28 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ - Clinical Lead
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
10.10 |
|
|
¿¥¾ÆÀ̾ËȦµù½º |
¿Ü±¹°è ÀÇ·á±â±â-QA Specialist
°æ±â ¾È¼º½Ã | ´ëÇÐ(2~3³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
09.21 |
|
|
Pharmax Ogilvy Healthworld |
Market Research Unit head (Â÷ºÎÀå±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
4³â¡è |
ä¿ë½Ã |
02.21 |
|
|
¸Æ½ºÈ£¶óÀÌÁð |
±¹³» À¯¸í ÀÇ·áÀç´Ü ¿¬±¸¼Ò (Medical Project Strategist)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
|
3³â¡è |
ä¿ë½Ã |
03.31 |
|
|
Æ÷Ƽ½ºÆÄÆ®³Ê½º |
¿Ü±¹°è Á¦¾à»ç ¸¶ÄÉÆà alliance mgr ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
4³â¡è |
ä¿ë½Ã |
09.16 |
|
|
Çѱ¹ÆúÁÖ½Äȸ»ç |
Biopharmaceutical Sales Engineer for Chromatography Prod
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
4³â¡è |
»ó½Ãä¿ë |
12.11 |
|